|Bid||115.05 x 800|
|Ask||115.15 x 1100|
|Day's Range||113.45 - 115.24|
|52 Week Range||61.13 - 118.96|
|Beta (5Y Monthly)||1.05|
|PE Ratio (TTM)||50.07|
|Earnings Date||Feb 16, 2021 - Feb 22, 2021|
|Forward Dividend & Yield||0.78 (0.68%)|
|Ex-Dividend Date||Jan 04, 2021|
|1y Target Est||119.13|
Agilent Technologies Inc. (NYSE: A) today announced its clinical informatics platform Alissa Interpret has been adopted by the North West Genomic Laboratory Hub (NW GLH) based in Manchester and Liverpool, part of Manchester University NHS Foundation Trust, England. The NW GLH and its partners are responsible for delivering genomic testing across the whole of the North West. Alissa Interpret, which enables clinical genetics labs to standardize and automate variant triage, review, classification, and reports on NGS data, becomes one of two platforms the NW GLH will use to analyze genomics data.
Agilent Technologies Inc. (NYSE: A) today announced a new ICP-MS instrument, the Agilent 7850 ICP-MS System, that provides new smart tools to minimize common time traps that can affect ICP-MS analysis workflows.
Agilent Technologies Inc. (NYSE: A) today announced the launch of the Biomarker Pathologist Training Program, a global initiative created to empower pathologists to score biomarkers accurately and confidently. Developed by Agilent – a worldwide leader in developing and commercializing diagnostic products – this training program incorporates Agilent’s unique expertise in companion diagnostics and partnership with top pharmaceutical companies.